
This review focuses on the clinical evidence supporting three nonsurgical treatments for BPH/LUTS in development: phosphodiesterase type-5 inhibitors, the intraprostatic instillation of onabotulinumtoxinA (BTA [Botox]), and gonadotropin-releasing hormone (GnRH) antagonists.